AutoPhagyGO is expanding clinical validation, scaling its supplement platform, and entering markets across the US, Europe, and China, partnering with companies like UHA Mikakuto to produce consumer-friendly products.

They emphasize that aging is not an inevitable decline but a modifiable process, advocating for lifestyle modifications and supplements to support this transformative view.

Their overarching mission is to develop safe, scalable interventions that measure and modulate autophagy, integrating traditional Japanese practices with modern technology to advance longevity science.

AutoPhagyGO, a Japanese team and semifinalist in the XPRIZE Healthspan competition, is pioneering an integrated approach to healthy aging by combining diet, supplementation, exercise, sleep, and advanced technology to enhance healthspan.

Their focus centers on leveraging autophagy, a cellular process recognized with a Nobel Prize, to promote longevity and healthy aging, with the goal of reshaping perceptions of aging as a modifiable process.

AutoPhagyGO aims to lead in measuring autophagy in humans, addressing a critical gap in longevity science, and plans to develop safe, scalable interventions that incorporate traditional Japanese lifestyle practices with modern tools like wearables, apps, and AI.

Their flagship supplement, Awabancha extract, has demonstrated a 14% lifespan extension in C. elegans, suggesting potential benefits for human longevity.

The team intends to show measurable improvements in muscle, cognition, and immunity within a year, aligning with the XPRIZE’s goal of compressing a decade of rejuvenation into just twelve months.

AutoPhagyGO highlights that autophagy complements other anti-aging therapies such as reprogramming and senolytics, emphasizing the safety and long history of their ingredients in dietary use.